GENERAL (Narrative) (Details)
$ / shares in Units, $ in Thousands

1 Months Ended

2 Months Ended

3 Months Ended

4 Months Ended

6 Months Ended

12 Months Ended

Jul. 08, 2025

USD ($)

Apr. 21, 2025

USD ($)

Aug. 06, 2019

USD ($)

Apr. 17, 2025

USD ($)

Apr. 15, 2025

Aug. 26, 2024

USD ($)

Aug. 23, 2024

$ / shares

Jul. 23, 2024

May 31, 2024

USD ($)

$ / shares

Mar. 28, 2024

USD ($)

Dec. 21, 2022

USD ($)

Aug. 31, 2022

USD ($)

Apr. 30, 2025

USD ($)

Dec. 31, 2024

USD ($)

$ / shares

Apr. 21, 2025

USD ($)

Jun. 30, 2025

USD ($)

Jun. 30, 2024

USD ($)

Dec. 31, 2024

USD ($)

Dec. 31, 2023

USD ($)

Dec. 31, 2022

USD ($)

Dec. 31, 2021

USD ($)

Jun. 30, 2025

₪ / shares

Jun. 30, 2025

USD ($)

$ / shares

Dec. 31, 2024

₪ / shares

Dec. 31, 2024

USD ($)

Aug. 23, 2023

Disclosure of detailed information about business combination [line items]

Operating loss

$ 6,098

$ 9,404

^[1]

Net operating cash outflows

(7,483)

(9,565)

Accumulated deficit

$ (281,121)

$ (274,071)

Ordinary shares issued | shares

8,714,230

6,514,589

Ordinary shares per share | ₪ / shares

₪ 0.2

Gross proceeds from ordinary shares

4,283

$ 86

Total consideration

$ 3,464

Aggregate offering price

$ 3

$ 695

$ 22

$ 2,600

Reverse share split ratio

1-for-10

Amount from redeem SAFE

$ 10,000

Subsequent Events [Member]

Disclosure of detailed information about business combination [line items]

Total consideration

$ 18,714

Definitive Agreement [Member]

Disclosure of detailed information about business combination [line items]

Ordinary shares issued | shares

265,000

Pre-funded warrants | shares

1,427,308

Pre-funded warrant per share | $ / shares

$ 0.0001

Biomica [Member] | Definitive Agreement [Member]

Disclosure of detailed information about business combination [line items]

Proportion of ownership interest in subsidiary

67.00%

ICL Group [Member]

Disclosure of detailed information about business combination [line items]

Total consideration

$ 15,250

Amount of investment under collaboration agreement

$ 10,000

ICL Group [Member] | Subsequent Events [Member]

Disclosure of detailed information about business combination [line items]

Gross proceeds from ordinary shares

4,415

Amount from redeem SAFE

$ 10,000

Shanghai Healthcare Capital [Member] | Biomica [Member] | Definitive Agreement [Member]

Disclosure of detailed information about business combination [line items]

Investments in subsidiaries reported in separate financial statements

$ 10,000

Total Amount Of Certain Convertible Loans

10,000

Amount of investment in financing round

$ 20,000

Proportion of ownership interest in subsidiary

20.00%

ATM offering [Member]

Disclosure of detailed information about business combination [line items]

Ordinary shares issued | shares

10,000

Sell price per share | $ / shares

$ 2.31

Gross proceeds from ordinary shares

$ 85

4,415

Aggregate offering price

$ 4,500

$ 7,300

$ 1,913,650

Weighted average share price | $ / shares

$ 8.5

Series A Ordinary Warrant [Member] | Definitive Agreement [Member]

Disclosure of detailed information about business combination [line items]

Exercise price per warrant | $ / shares

3.55

Number of ordinary shares sold | shares

1,692,308

Series B Ordinary Warrant [Member] | Definitive Agreement [Member]

Disclosure of detailed information about business combination [line items]

Exercise price per warrant | $ / shares

3.55

$ 1,146,308

Aggregate offering price

$ 281,000

$ 1,146,308

Series A And B Ordinary Warrant [Member] | Definitive Agreement [Member]

Disclosure of detailed information about business combination [line items]

Gross proceeds from ordinary shares

$ 5,500

Purchase price per share | $ / shares

$ 3.25

Lavie Bio Ltd [Member]

Disclosure of detailed information about business combination [line items]

Investments in subsidiaries reported in separate financial statements

$ 10,000

Ownership percentage held by other entity in subsidiary

27.84%

Lavie Bio Ltd [Member] | ICL Group [Member] | Subsequent Events [Member]

Disclosure of detailed information about business combination [line items]

Amount from redeem SAFE

$ 10,000

[1]	Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

Evogene Ltd. 6-K